Drug Discovery & Pharmaceuticals

RSS

New funding to accelerate development of potential anti-cancer compound into the clinic

For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents.

28 Feb 2023

New purification approach could help make protein drugs more affordable and accessible

One of the most expensive steps in manufacturing protein drugs such as antibodies or insulin is the purification step: isolating the protein from the bioreactor used to produce it.

28 Feb 2023

First small molecules designed to stimulate immune cells against neuroblastoma

An MUSC Hollings Cancer Center research team has created what team members believe to be among the first small molecules designed to stimulate immune cells to fight cancer.

28 Feb 2023

St. Jude researchers show how drug makers can avoid toxicity and resistance

Scientists at St. Jude Children's Research Hospital have demonstrated how drug makers can avoid two key problems: toxicity and resistance.

28 Feb 2023

Using the origami technique to design RNA nanostructures

Researchers from Aarhus University and Berkeley Laboratory have designed RNA molecules, that folds into nanoscale rectangles, cylinders, and satellites, and have studied their 3D structure and dynamics with advanced nanotechnological methods.

28 Feb 2023

Tecan and Oxford Nanopore build alliance to create automated, seamless and fully compatible nanopore sequencing library preparation for any-length fragments of native DNA/RNA

The Tecan Group and Oxford Nanopore Technologies plc (Oxford Nanopore) today announce their collaboration to drive easier high-throughput nanopore library preparation in an automated, hands-free fashion.

From Tecan 27 Feb 2023

BICO introduces new life sciences manufacturing platform integrating ABB Robotics technology

BICO Group’s business area Bioautomation is expanding its manufacturing product offering by introducing The Nucleus™ Automation Ecosystem, a fully integrated platform bringing a new level of modularity, flexibility and scalability to the manufacturing market.

From SCIENION GmbH 27 Feb 2023

Study analyzes the potential of a natural amino acid as new way to cure COVID-19

After more than two years since its discovery, six million deaths, and half a billion reported cases, there is still no effective cure for COVID-19. Even though vaccines have lowered the impact of outbreaks, patients that contract the disease can only receive supportive care while they wait for their own body to clear the infection.

24 Feb 2023

Difference between human and mouse lung tumor cells explains the discrepancy in cancer drug results

A small but significant metabolic difference between human and mouse lung tumor cells, has been discovered by Weill Cornell Medicine researchers, explaining a discrepancy in previous study results, and pointing toward new strategies for developing cancer treatments.

24 Feb 2023

Organoid models for research on Chinese herbal medicine

Announcing a new publication for Acta Materia Medica journal. Organoids are three-dimensional cell accusations generated from pluripotent stem cells or adult stem cells in vitro.

24 Feb 2023

Study finds high doses of oral CBD can exacerbate THC’s effects by inhibiting THC metabolism

Researchers compare the pharmacokinetics and pharmacodynamics of oral Δ9-tetrahydrocannabinol-dominant and cannabidiol-dominant cannabis extracts that contained the same Δ9-THC dose (20 mg).

24 Feb 2023

A network of interacting proteins created to aid drug discovery

Scientists at Open Targets, EMBL's European Bioinformatics Institute, and GSK are revealing the shared basis of diseases using a map of interacting human proteins.

24 Feb 2023

Ingenza appoints new Strategic Business Advisor

Ingenza is excited to welcome Dr Mark Chadwick to the team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position at Ingenza, acquired over 30 years from a variety of roles within small growth companies, covering the areas of biotechnology, drug discovery and drug development.

23 Feb 2023

New prototype treatment proves effective against the venom of African and Asian elapid snakes

Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.

23 Feb 2023

Novel fatty liver organoid models could aid in drug discovery and testing

Researchers from the Organoid group (former Clevers group, Hubrecht Institute) together with researchers from the Princess Máxima Center for pediatric oncology established novel human organoid models of fatty liver disease.

23 Feb 2023

Scientific advice on the terminal sterilization of oligonucleotide drug products

A new report, coauthored by several major pharmaceutical companies, reviews the current state of sterile oligonucleotide drug product processing.

22 Feb 2023

Brexanolone inhibits key systemic inflammatory pathways associated with post-partum depression

Post-partum depression (PPD) develops after childbirth and affects both the mother's and the infant's health by preventing healthy bonding.

20 Feb 2023

Activating or deactivating drugs with the help of light

Scientists at the Paul Scherrer Institute PSI have used the Swiss X-ray free-electron laser SwissFEL and the Swiss Light Source SLS to make a film that could give a decisive boost to developing a new type of drug.

20 Feb 2023

LLNL licensee and collaborators develop novel medicines to combat autoimmune diseases

People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory licensee and its' collaborations with two major pharmaceutical companies.

17 Feb 2023

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

16 Feb 2023

Drug Discovery & Pharmaceuticals

New funding to accelerate development of potential anti-cancer compound into the clinic

New purification approach could help make protein drugs more affordable and accessible

First small molecules designed to stimulate immune cells against neuroblastoma

St. Jude researchers show how drug makers can avoid toxicity and resistance

Using the origami technique to design RNA nanostructures

Tecan and Oxford Nanopore build alliance to create automated, seamless and fully compatible nanopore sequencing library preparation for any-length fragments of native DNA/RNA

BICO introduces new life sciences manufacturing platform integrating ABB Robotics technology

Study analyzes the potential of a natural amino acid as new way to cure COVID-19

Difference between human and mouse lung tumor cells explains the discrepancy in cancer drug results

Organoid models for research on Chinese herbal medicine

Study finds high doses of oral CBD can exacerbate THC’s effects by inhibiting THC metabolism

A network of interacting proteins created to aid drug discovery

Ingenza appoints new Strategic Business Advisor

New prototype treatment proves effective against the venom of African and Asian elapid snakes

Novel fatty liver organoid models could aid in drug discovery and testing

Scientific advice on the terminal sterilization of oligonucleotide drug products

Brexanolone inhibits key systemic inflammatory pathways associated with post-partum depression

Activating or deactivating drugs with the help of light

LLNL licensee and collaborators develop novel medicines to combat autoimmune diseases

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest Life Science News